A nomenclature and classification for the congenital myasthenic syndromes: preparing for FAIR data in the genomic era

Rachel Thompson, Angela Abicht, David Beeson, Andrew G Engel, Bruno Eymard, Emmanuel Maxime, Hanns Lochmüller

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Congenital myasthenic syndromes (CMS) are a heterogeneous group of inherited neuromuscular disorders sharing the common feature of fatigable weakness due to defective neuromuscular transmission. Despite rapidly increasing knowledge about the genetic origins, specific features and potential treatments for the known CMS entities, the lack of standardized classification at the most granular level has hindered the implementation of computer-based systems for knowledge capture and reuse. Where individual clinical or genetic entities do not exist in disease coding systems, they are often invisible in clinical records and inadequately annotated in information systems, and features that apply to one disease but not another cannot be adequately differentiated. Results: We created a detailed classification of all CMS disease entities suitable for use in clinical and genetic databases and decision support systems. To avoid conflict with existing coding systems as well as with expert-defined group-level classifications, we developed a collaboration with the Orphanet nomenclature for rare diseases, creating a clinically understandable name for each entity and placing it within a logical hierarchy that paves the way towards computer-aided clinical systems and improved knowledge bases for CMS that can adequately differentiate between types and ascribe relevant expert knowledge to each. Conclusions: We suggest that data science approaches can be used effectively in the clinical domain in a way that does not disrupt preexisting expert classification and that enhances the utility of existing coding systems. Our classification provides a comprehensive view of the individual CMS entities in a manner that supports differential diagnosis and understanding of the range and heterogeneity of the disease but that also enables robust computational coding and hierarchy for machine-readability. It can be extended as required in the light of future scientific advances, but already provides the starting point for the creation of FAIR (Findable, Accessible, Interoperable and Reusable) knowledge bases of data on the congenital myasthenic syndromes.

Original languageEnglish (US)
Article number211
JournalOrphanet Journal of Rare Diseases
Volume13
Issue number1
DOIs
StatePublished - Nov 26 2018

Fingerprint

Congenital Myasthenic Syndromes
Terminology
Knowledge Bases
Genetic Databases
Computer Systems
Rare Diseases
Information Systems
Names
Differential Diagnosis

Keywords

  • Classification
  • CMS
  • Coding
  • Congenital myasthenic syndromes
  • Neuromuscular disease
  • Neuromuscular junction
  • Nomenclature
  • Nosology
  • Ontology
  • Rare disease

ASJC Scopus subject areas

  • Genetics(clinical)
  • Pharmacology (medical)

Cite this

A nomenclature and classification for the congenital myasthenic syndromes : preparing for FAIR data in the genomic era. / Thompson, Rachel; Abicht, Angela; Beeson, David; Engel, Andrew G; Eymard, Bruno; Maxime, Emmanuel; Lochmüller, Hanns.

In: Orphanet Journal of Rare Diseases, Vol. 13, No. 1, 211, 26.11.2018.

Research output: Contribution to journalArticle

Thompson, Rachel ; Abicht, Angela ; Beeson, David ; Engel, Andrew G ; Eymard, Bruno ; Maxime, Emmanuel ; Lochmüller, Hanns. / A nomenclature and classification for the congenital myasthenic syndromes : preparing for FAIR data in the genomic era. In: Orphanet Journal of Rare Diseases. 2018 ; Vol. 13, No. 1.
@article{13c6308fcc5e4c0fac95f03cc75ed5c6,
title = "A nomenclature and classification for the congenital myasthenic syndromes: preparing for FAIR data in the genomic era",
abstract = "Background: Congenital myasthenic syndromes (CMS) are a heterogeneous group of inherited neuromuscular disorders sharing the common feature of fatigable weakness due to defective neuromuscular transmission. Despite rapidly increasing knowledge about the genetic origins, specific features and potential treatments for the known CMS entities, the lack of standardized classification at the most granular level has hindered the implementation of computer-based systems for knowledge capture and reuse. Where individual clinical or genetic entities do not exist in disease coding systems, they are often invisible in clinical records and inadequately annotated in information systems, and features that apply to one disease but not another cannot be adequately differentiated. Results: We created a detailed classification of all CMS disease entities suitable for use in clinical and genetic databases and decision support systems. To avoid conflict with existing coding systems as well as with expert-defined group-level classifications, we developed a collaboration with the Orphanet nomenclature for rare diseases, creating a clinically understandable name for each entity and placing it within a logical hierarchy that paves the way towards computer-aided clinical systems and improved knowledge bases for CMS that can adequately differentiate between types and ascribe relevant expert knowledge to each. Conclusions: We suggest that data science approaches can be used effectively in the clinical domain in a way that does not disrupt preexisting expert classification and that enhances the utility of existing coding systems. Our classification provides a comprehensive view of the individual CMS entities in a manner that supports differential diagnosis and understanding of the range and heterogeneity of the disease but that also enables robust computational coding and hierarchy for machine-readability. It can be extended as required in the light of future scientific advances, but already provides the starting point for the creation of FAIR (Findable, Accessible, Interoperable and Reusable) knowledge bases of data on the congenital myasthenic syndromes.",
keywords = "Classification, CMS, Coding, Congenital myasthenic syndromes, Neuromuscular disease, Neuromuscular junction, Nomenclature, Nosology, Ontology, Rare disease",
author = "Rachel Thompson and Angela Abicht and David Beeson and Engel, {Andrew G} and Bruno Eymard and Emmanuel Maxime and Hanns Lochm{\"u}ller",
year = "2018",
month = "11",
day = "26",
doi = "10.1186/s13023-018-0955-7",
language = "English (US)",
volume = "13",
journal = "Orphanet Journal of Rare Diseases",
issn = "1750-1172",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - A nomenclature and classification for the congenital myasthenic syndromes

T2 - preparing for FAIR data in the genomic era

AU - Thompson, Rachel

AU - Abicht, Angela

AU - Beeson, David

AU - Engel, Andrew G

AU - Eymard, Bruno

AU - Maxime, Emmanuel

AU - Lochmüller, Hanns

PY - 2018/11/26

Y1 - 2018/11/26

N2 - Background: Congenital myasthenic syndromes (CMS) are a heterogeneous group of inherited neuromuscular disorders sharing the common feature of fatigable weakness due to defective neuromuscular transmission. Despite rapidly increasing knowledge about the genetic origins, specific features and potential treatments for the known CMS entities, the lack of standardized classification at the most granular level has hindered the implementation of computer-based systems for knowledge capture and reuse. Where individual clinical or genetic entities do not exist in disease coding systems, they are often invisible in clinical records and inadequately annotated in information systems, and features that apply to one disease but not another cannot be adequately differentiated. Results: We created a detailed classification of all CMS disease entities suitable for use in clinical and genetic databases and decision support systems. To avoid conflict with existing coding systems as well as with expert-defined group-level classifications, we developed a collaboration with the Orphanet nomenclature for rare diseases, creating a clinically understandable name for each entity and placing it within a logical hierarchy that paves the way towards computer-aided clinical systems and improved knowledge bases for CMS that can adequately differentiate between types and ascribe relevant expert knowledge to each. Conclusions: We suggest that data science approaches can be used effectively in the clinical domain in a way that does not disrupt preexisting expert classification and that enhances the utility of existing coding systems. Our classification provides a comprehensive view of the individual CMS entities in a manner that supports differential diagnosis and understanding of the range and heterogeneity of the disease but that also enables robust computational coding and hierarchy for machine-readability. It can be extended as required in the light of future scientific advances, but already provides the starting point for the creation of FAIR (Findable, Accessible, Interoperable and Reusable) knowledge bases of data on the congenital myasthenic syndromes.

AB - Background: Congenital myasthenic syndromes (CMS) are a heterogeneous group of inherited neuromuscular disorders sharing the common feature of fatigable weakness due to defective neuromuscular transmission. Despite rapidly increasing knowledge about the genetic origins, specific features and potential treatments for the known CMS entities, the lack of standardized classification at the most granular level has hindered the implementation of computer-based systems for knowledge capture and reuse. Where individual clinical or genetic entities do not exist in disease coding systems, they are often invisible in clinical records and inadequately annotated in information systems, and features that apply to one disease but not another cannot be adequately differentiated. Results: We created a detailed classification of all CMS disease entities suitable for use in clinical and genetic databases and decision support systems. To avoid conflict with existing coding systems as well as with expert-defined group-level classifications, we developed a collaboration with the Orphanet nomenclature for rare diseases, creating a clinically understandable name for each entity and placing it within a logical hierarchy that paves the way towards computer-aided clinical systems and improved knowledge bases for CMS that can adequately differentiate between types and ascribe relevant expert knowledge to each. Conclusions: We suggest that data science approaches can be used effectively in the clinical domain in a way that does not disrupt preexisting expert classification and that enhances the utility of existing coding systems. Our classification provides a comprehensive view of the individual CMS entities in a manner that supports differential diagnosis and understanding of the range and heterogeneity of the disease but that also enables robust computational coding and hierarchy for machine-readability. It can be extended as required in the light of future scientific advances, but already provides the starting point for the creation of FAIR (Findable, Accessible, Interoperable and Reusable) knowledge bases of data on the congenital myasthenic syndromes.

KW - Classification

KW - CMS

KW - Coding

KW - Congenital myasthenic syndromes

KW - Neuromuscular disease

KW - Neuromuscular junction

KW - Nomenclature

KW - Nosology

KW - Ontology

KW - Rare disease

UR - http://www.scopus.com/inward/record.url?scp=85057263588&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057263588&partnerID=8YFLogxK

U2 - 10.1186/s13023-018-0955-7

DO - 10.1186/s13023-018-0955-7

M3 - Article

C2 - 30477555

AN - SCOPUS:85057263588

VL - 13

JO - Orphanet Journal of Rare Diseases

JF - Orphanet Journal of Rare Diseases

SN - 1750-1172

IS - 1

M1 - 211

ER -